These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19733152)

  • 21. L'RRK de Triomphe: a solution for LRRK2 GTPase activity?
    Nixon-Abell J; Berwick DC; Harvey K
    Biochem Soc Trans; 2016 Dec; 44(6):1625-1634. PubMed ID: 27913671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
    Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding.
    Taymans JM; Vancraenenbroeck R; Ollikainen P; Beilina A; Lobbestael E; De Maeyer M; Baekelandt V; Cookson MR
    PLoS One; 2011; 6(8):e23207. PubMed ID: 21858031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations.
    Rudi K; Ho FY; Gilsbach BK; Pots H; Wittinghofer A; Kortholt A; Klare JP
    Biosci Rep; 2015 Aug; 35(5):. PubMed ID: 26310572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
    Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
    PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
    Nguyen AP; Moore DJ
    Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
    Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD
    J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leucine-rich repeat kinase 2: relevance to Parkinson's disease.
    Guo L; Wang W; Chen SG
    Int J Biochem Cell Biol; 2006; 38(9):1469-75. PubMed ID: 16600664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
    West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM
    Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The GTPase function of LRRK2.
    Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1063-9. PubMed ID: 22988866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
    Zhang X; Kortholt A
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations.
    Mills RD; Mulhern TD; Cheng HC; Culvenor JG
    Biochem Soc Trans; 2012 Oct; 40(5):1086-9. PubMed ID: 22988870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
    Seol W
    BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
    Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
    Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.
    Ito G; Okai T; Fujino G; Takeda K; Ichijo H; Katada T; Iwatsubo T
    Biochemistry; 2007 Feb; 46(5):1380-8. PubMed ID: 17260967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2.
    Li X; Moore DJ; Xiong Y; Dawson TM; Dawson VL
    J Biol Chem; 2010 Sep; 285(38):29569-76. PubMed ID: 20595391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
    Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M
    Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
    Greggio E
    Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Parkinson disease gene LRRK2: evolutionary and structural insights.
    Marín I
    Mol Biol Evol; 2006 Dec; 23(12):2423-33. PubMed ID: 16966681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.